Eye Fixation-Related Potentials during Visual Search on Acquaintance and Newly-Learned Faces.

Searching familiar faces in the crowd may involve stimulus-driven attention by emotional significance, together with goal-directed attention due to task-relevant needs. The present study investigated the effect of familiarity on attentional processes by exploring eye fixation-related potentials (EFRPs) and eye gazes when humans searched for, among other distracting faces, either an acquaintance's face or a newly-learned face. Task performance and gaze behavior were indistinguishable for identifying either faces. However, from the EFRP analysis, after a P300 component for successful search of target faces, we found greater deflections of right parietal late positive potentials in response to newly-learned faces than acquaintance's faces, indicating more involvement of goal-directed attention in processing newly-learned faces. In addition, we found greater occipital negativity elicited by acquaintance's faces, reflecting emotional responses to significant stimuli. These results may suggest that finding a familiar face in the crowd would involve lower goal-directed attention and elicit more emotional responses.

A Wearable Wrist Band-Type System for Multimodal Biometrics Integrated with Multispectral Skin Photomatrix and Electrocardiogram Sensors.

Multimodal biometrics are promising for providing a strong security level for personal authentication, yet the implementation of a multimodal biometric system for practical usage need to meet such criteria that multimodal biometric signals should be easy to acquire but not easily compromised. We developed a wearable wrist band integrated with multispectral skin photomatrix (MSP) and electrocardiogram (ECG) sensors to improve the issues of collectability, performance and circumvention of multimodal biometric authentication. The band was designed to ensure collectability by sensing both MSP and ECG easily and to achieve high authentication performance with low computation, efficient memory usage, and relatively fast response. Acquisition of MSP and ECG using contact-based sensors could also prevent remote access to personal data. Personal authentication with multimodal biometrics using the integrated wearable wrist band was evaluated in 150 subjects and resulted in 0.2% equal error rate ( EER ) and 100% detection probability at 1% FAR (false acceptance rate) ( PD . 1 ), which is comparable to other state-of-the-art multimodal biometrics. An additional investigation with a separate MSP sensor, which enhanced contact with the skin, along with ECG reached 0.1% EER and 100% PD . 1 , showing a great potential of our in-house wearable band for practical applications. The results of this study demonstrate that our newly developed wearable wrist band may provide a reliable and easy-to-use multimodal biometric solution for personal authentication.

Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts.

The vascular endothelial growth factor-A (VEGF-A) signaling pathway, a key stimulant of solid tumor vascularization, is primarily dependent on the activation of the endothelial cell surface receptor VEGF receptor-2 (VEGFR-2). AZD2171 is an oral, highly potent small-molecule inhibitor of VEGFR tyrosine kinase activity that inhibits angiogenesis and the growth of human tumor xenografts in vivo. Here, we show pharmacodynamic changes in VEGFR-2 phosphorylation induced by AZD2171. In mouse lung tissue, a single dose of AZD2171 at 6 mg/kg inhibited VEGF-A-stimulated VEGFR-2 phosphorylation by 87% at 2 h with significant inhibition (>or=60%) maintained to 24 h. To examine inhibition of VEGFR-2 phosphorylation in tumor vasculature by immunohistochemistry, a comprehensive assessment of antibodies to various phosphorylation sites on the receptor was undertaken. Antibodies to the phosphotyrosine epitopes pY1175/1173 and pY1214/1212 were found suitable for this application. Calu-6 human lung tumor xenografts, from mice receiving AZD2171 or vehicle treatment (p.o., once daily), were examined by immunohistochemistry. A significant reduction in tumor vessel staining of phosphorylated VEGFR-2 (pVEGFR-2) was evident within 28 h of AZD2171 treatment (6 mg/kg). This effect preceded a significant reduction in tumor microvessel density, which was detectable following 52 h of AZD2171 treatment. These data show that AZD2171 is a potent inhibitor of VEGFR-2 activation in vivo and suggest that AZD2171 delivers therapeutic benefit in Calu-6 tumors by targeting vessels dependent on VEGFR-2 signaling for survival. In addition, this work highlights the utility of measuring either pY1175/1173 or pY1214/1212 on VEGFR-2 as a pharmacodynamic marker of VEGFR-2 activation.